Abstract
ObjectiveTo analyze the relationship between tumor size and metastatic site in stage IV NSCLC patients.MethodsA total of 40,196 stage IV NSCLC patients from 2010 to 2015 were screened by SEER database. Chi-square test was used to compare the characteristics of clinical variables. At the same time, multivariate Logistic regression analysis was used to evaluate the relationship between tumor size and organ metastasis.ResultsRegardless of tumor size, the proportion of bone metastasis and lung metastasis was higher and similar in patients with squamous cell carcinoma, while in patients with adenocarcinoma, bone metastasis accounted for the highest proportion. We found that whether the metastatic site was bone, brain, liver or lung, the proportion of patients with a tumor size of 3–7 cm was the highest. Multivariate regression analysis demonstrated that patients with a tumor size of 3–7 cm and a tumor size ≥7 cm were more likely to develop brain metastasis and lung metastasis compared with patients with a tumor size ≤3 cm (all P < 0.001), which meant the larger the tumor, the greater the risk of brain or lung metastasis. At the same time, the results indicated that patients with a tumor size of 3–7 cm had a tendency to develop liver metastasis (P = 0.004), while the statistical significance was not found for patients with a tumor size ≥7 cm (P = 0.524). The results also revealed that patients with a tumor size of 3–7cm had no significant difference to develop bone metastasis (P = 0.116), while the statistical significance was found for patients with a tumor size ≥7 cm (P < 0.001).ConclusionsThere was statistical significance between tumor size and metastatic site in patients with stage IV NSCLC. For brain or lung metastasis, the larger the tumor, the higher the risk of brain or lung metastasis. For liver metastasis, patients with a tumor size of 3–7 cm were more prone to develop liver metastasis. For bone metastasis, patients with a tumor size ≥7 cm were more likely to have bone metastasis.
Highlights
Lung cancer is one of the most common malignancies and the leading cause of cancer death (Siegel, Miller & Jemal, 2018)
About 85% of lung cancer patients were diagnosed with non-small cell lung cancer (NSCLC), and approximately 40% were diagnosed with metastatic disease at the time of onset
The results showed that patients with a tumor size of 3–7 cm and a tumor size ≥7 cm were more likely to develop brain metastasis and lung metastasis compared with patients with a tumor size ≤3 cm, which
Summary
Lung cancer is one of the most common malignancies and the leading cause of cancer death (Siegel, Miller & Jemal, 2018). About 85% of lung cancer patients were diagnosed with non-small cell lung cancer (NSCLC), and approximately 40% were diagnosed with metastatic disease at the time of onset. About 30% to 40% of NSCLC patients had bone metastasis during the course of their disease, and more than 60% of them had bone lesions at the initial diagnosis (Saad et al, 2007; Tsuya et al, 2007). Saad et al (2008) showed that about 10% of NSCLC patients developed brain metastasis at the initial diagnosis, and 40–50% of NSCLC patients developed brain metastasis during the course of the disease. A retrospective study of 409 patients with stage IV non-small cell lung cancer showed that patients with liver metastasis had lower overall survival (OS) (Badawy et al, 2018)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
